| These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0 .1%, for topical use Initial U.S. Approval: 1997 | Mayne Pharma | DPT Laboratories, Ltd. | 20260303 | 7 |
| These highlights do not include all the information needed to use TAZAROTENE CREAM safely and effectively. See full prescribing information for TAZAROTENE CREAM. TAZAROTENE cream, for topical use Initial U.S. Approval: 1997 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc. | 20251219 | 6 |
| These highlights do not include all the information needed to use TAZORAC ® Cream safely and effectively. See full prescribing information for TAZORAC ® Cream. TAZORAC ® (tazarotene) cream, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Almirall, LLC | 20251113 | 6 |
| These highlights do not include all the information needed to use TAZORAC ® Gel safely and effectively. See full prescribing information for TAZORAC ® Gel. TAZORAC ® (tazarotene) gel, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Almirall, LLC | 20251113 | 4 |
| These highlights do not include all the information needed to use TAZAROTENE CREAM safely and effectively. See full prescribing information for TAZAROTENE CREAM. TAZAROTENE cream, for topical use Initial U.S. Approval: 1997 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc. | 20250707 | 6 |
| These highlights do not include all the information needed to use TAZAROTENE CREAM safely and effectively. See full prescribing information for TAZAROTENE CREAM. TAZAROTENE cream, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Cosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20250310 | 8 |
| These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Solaris Pharma Corporation | 20250102 | 4 |
| These highlights do not include all the information needed to use TAZAROTENE CREAM safely and effectively. See full prescribing information for TAZAROTENE CREAM. TAZAROTENE cream, 0.05% for topical use Initial U.S. Approval: 1997 | Bryant Ranch Prepack | 20241111 | 100 |
| These highlights do not include all the information needed to use Tazarotene Foam safely and effectively. See full prescribing information for Tazarotene Foam. Tazarotene Foam, 0 .1%, for topical use Initial U.S. Approval: 1997 | Mayne Pharma Inc. | DPT Laboratories, Ltd. | 20240604 | 3 |
| These highlights do not include all the information needed to use TAZAROTENE CREAM safely and effectively. See full prescribing information for TAZAROTENE CREAM. TAZAROTENE cream, 0.05% for topical use Initial U.S. Approval: 1997 | Padagis Israel Pharmaceuticals Ltd | 20240531 | 2 |
| These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Bryant Ranch Prepack | 20240529 | 101 |
| These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05% and 0.1%, for topical use Initial U.S. Approval: 1997 | Padagis Israel Pharmaceuticals Ltd | 20240101 | 3 |
| PSO THERA Scalp Psoriasis Shampoo | PSODEX USA INC | BERKO ILAC VE KIMYA SANAYI ANONIM SIRKETI-SULTANBEYLI SUBESI | 20231221 | 2 |
| Tazarodex Cream Plaque Psoriasis & Acne | PSODEX USA INC | BERKO ILAC VE KIMYA SANAYI ANONIM SIRKETI-SULTANBEYLI SUBESI | 20231221 | 3 |
| These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.05%, for topical use Initial U.S. Approval: 1997 | Cosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20231129 | 2 |
| These highlights do not include all the information needed to use TAZAROTENE GEL safely and effectively. See full prescribing information for TAZAROTENE GEL. TAZAROTENE gel, 0.1%, for topical use Initial U.S. Approval: 1997 | Cosette Pharmaceuticals, Inc. | Cosette Pharmaceuticals NC Laboratories, LLC | 20231129 | 2 |
| These highlights do not include all the information needed to use ARAZLO safely and effectively. See full prescribing information for ARAZLO. ARAZLO ® (tazarotene) lotion, for topical use Initial U.S. Approval: 1997 | Bausch Health US, LLC | Bausch Health Companies Inc. | 20230926 | 5 |
| 011312 NIACINAMIDE 4% / TAZAROTENE 0.05% | Sincerus Florida, LLC | 20200702 | 1 |
| These highlights do not include all the information needed to use DUOBRII safely and effectively. See full prescribing information for DUOBRII. DUOBRII ® (halobetasol propionate and tazarotene) lotion, for topical use Initial U.S. Approval: 2019 | Bausch Health US, LLC | Bausch Health Companies Inc. | 20200101 | 6 |
| CLINDAMYCIN 1% / NIACINAMIDE 2% / TAZAROTENE 0.05% | Sincerus Florida, LLC | 20190509 | 1 |
| HYALURONIC ACID SODIUM SALT 0.5% / TAZAROTENE 0.05% | Sincerus Florida, LLC | 20190509 | 1 |
| NIACINAMIDE 4% / TAZAROTENE 0.1% | Sincerus Florida, LLC | 20190509 | 1 |
| HYALURONIC ACID SODIUM SALT 0.5% / TAZAROTENE 0.1% | Sincerus Florida, LLC | 20190506 | 1 |
| NIACINAMIDE 4% / TAZAROTENE 0.05% | Sincerus Florida, LLC | 20190423 | 1 |
| NIACINAMIDE 4% / TAZAROTENE 0.1% | Sincerus Florida, LLC | 20190423 | 1 |
| b2fbd294-5fb9-45bc-baf0-8c5b72bddb74 | Physicians Total Care, Inc. | 20101022 | 1 |